Optimal timing of radical cystectomy in T1 high-grade bladder cancer

References

• Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology66(6 Suppl. 1), 4–34 (2005).
   PubMed Web of Science ®Google Scholar
• Mostofi F, Sobin L, Torloni H. Histological typing of urinary bladder tumors. In: International Classification of Tumors. WHO, Geneva, Switzerland (1973).
   Google Scholar
• Eble J, Sauter G, Epstein J, Sesterhenn I. The World Health Organization Classification of Tumors of the Urinary System and Male Genital System. IARC Press, Lyon, France (2004).
   Google Scholar
• Bostrom P, van Rhijn B, Fleshner N et al. Staging and staging errors in bladder cancer. Eur. Urol. Suppl.9(1), 2–9 (2010).
   Web of Science ®Google Scholar
• Fritsche H, Burger M, Svatek R et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur. Urol.57(2), 300–309 (2010).
   PubMed Web of Science ®Google Scholar
• Cheng L, Neumann R, Weaver A et al. Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cystectomy specimens. Am. J. Clin. Pathol.113(2), 275–279 (2000).
   PubMed Web of Science ®Google Scholar
• Divrik R, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J. Urol.175(5), 1641–1644 (2006).
   PubMed Web of Science ®Google Scholar
• Younes M, Sussman J, True L. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer66(3), 543–548 (1990).
   PubMed Web of Science ®Google Scholar
• Holmäng S, Hedelin H, Anderström C, Holmberg E, Johansson S. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J. Urol.157(3), 800–803 (1997).
   PubMed Web of Science ®Google Scholar
• Orsola A, Trias I, Raventós C et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur. Urol.48(2), 231–238 (2005).
   PubMed Web of Science ®Google Scholar
• Cheng L, Weaver A, Neumann R, Scherer B, Bostwick D. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer86(6), 1035–1043 (1999).
   PubMed Web of Science ®Google Scholar
• Cheng L, Neumann R, Weaver A, Spotts B, Bostwick D. Predicting cancer progression in patients with stage T1 bladder carcinoma. J. Clin. Oncol.17(10), 3182–3187 (1999).
   PubMed Web of Science ®Google Scholar
• van der Aa M, van Leenders G, Steyerberg E et al. A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum. Pathol.36(9), 981–986 (2005).
   PubMed Web of Science ®Google Scholar
• Paner G, Brown J, Lapetino S et al. Diagnostic use of antibody to smoothelin in the recognition of muscularis propria in transurethral resection of urinary bladder tumor (TURBT) specimens. Am. J. Surg. Pathol.34(6), 792–799 (2010).
   Google Scholar
• Duchek M, Johansson R, Jahnson S et al. Bacillus Calmette–Guérin is superior to a combination of epirubicin and interferon-α2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur. Urol.57(1), 25–31 (2010).
   PubMed Web of Science ®Google Scholar
• Orsola A, Cecchini L, Raventós C et al. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette–Guérin therapy and the decision for a repeat TUR. BJU Int.105(2), 202–207 (2010).
   Google Scholar
• Han K, Joung J, Cho K et al. Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature. J. Endourol.22(12), 2699–2704 (2008).
   PubMed Web of Science ®Google Scholar
• Schwaibold H, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int.97(6), 1199–1201 (2006).
   PubMed Web of Science ®Google Scholar
• Schips L, Augustin H, Zigeuner R et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology59(2), 220–223 (2002).
   PubMed Web of Science ®Google Scholar
• Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J. Urol.165(3), 808–810 (2001).
   PubMed Web of Science ®Google Scholar
• Rigaud J, Karam G, Braud G, Glemain P, Buzelin J, Bouchot O. [T1 bladder tumors: value of a second endoscopic resection]. Prog. Urol.12(1), 27–30 (2002).
   Google Scholar
• Herr H. The value of a second transurethral resection in evaluating patients with bladder tumors. J. Urol.162(1), 74–76 (1999).
   PubMed Web of Science ®Google Scholar
• Klän R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J. Urol.146(2), 316–318 (1991).
   PubMed Web of Science ®Google Scholar
• Dutta S, Smith JJ, Shappell S, Coffey C, Chang S, Cookson M. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J. Urol.166(2), 490–493 (2001).
   PubMed Web of Science ®Google Scholar
• Bol M, Baak J, Buhr-Wildhagen S et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J. Urol.169(4), 1291–1294 (2003).
   PubMed Web of Science ®Google Scholar
• Herr H, Donat S. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int.97(6), 1194–1198 (2006).
   PubMed Web of Science ®Google Scholar
• Divrik R, Sahin A, Yildirim U, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur. Urol.58(2), 185–190 (2010).
   PubMed Web of Science ®Google Scholar
• Van Der Meijden A, Sylvester R, Collette L, Bono A, Ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J. Urol.164(5), 1533–1537 (2000).
   PubMed Web of Science ®Google Scholar
• van Rhijn B, van der Kwast T, Kakiashvili D et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int.106(2), 206–211 (2009).
   PubMed Web of Science ®Google Scholar
• Lee M, Levin H, Jones J. The role of pathology review of transurethral bladder tumor resection specimens in the modern era. J. Urol.183(3), 921–927 (2010).
   PubMedGoogle Scholar
• Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol.54(2), 303–314 (2008).
   PubMed Web of Science ®Google Scholar
• Jakse G, Loidl W, Seeber G, Hofstädter F. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J. Urol.137(1), 39–43 (1987).
   PubMed Web of Science ®Google Scholar
• Heney N, Ahmed S, Flanagan M et al. Superficial bladder cancer: progression and recurrence. J. Urol.130(6), 1083–1086 (1983).
   PubMed Web of Science ®Google Scholar
• Abel P, Hall R, Williams G. Should pT1 transitional cell cancers of the bladder still be classified as superficial? Br. J. Urol.62(3), 235–239 (1988).
   PubMedGoogle Scholar
• Shahin O, Thalmann G, Rentsch C, Mazzucchelli L, Studer U. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette–Guérin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J. Urol.169(1), 96–100 (2003).
   PubMed Web of Science ®Google Scholar
• Mulders P, Hoekstra W, Heybroek R et al. Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study Group. Eur. J. Cancer30A(7), 914–917 (1994).
   Google Scholar
• Nieder A, Brausi M, Lamm D et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology66(6 Suppl. 1), 108–125 (2005).
   PubMed Web of Science ®Google Scholar
• Sylvester R, van der Meijden A, Lamm D. Intravesical bacillus Calmette–Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol.168(5), 1964–1970 (2002).
   PubMed Web of Science ®Google Scholar
• Kulkarni G, Hakenberg O, Gschwend J et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur. Urol.57(1), 60–70 (2010).
   PubMed Web of Science ®Google Scholar
• Kakiashvili DM, Van Rhijn BW, Trottier G et al. Long term follow-up of T1 high grade bladder cancer after intravesical BCG treatment. BJU Int. DOI: 10.1111/j.1464-410X.2010.09572.x (2010) (Epub ahead of print).
   Google Scholar
• Alkhateeb S, Van Rhijn B, Finelli A et al. Nonprimary pT1 Nonmuscle invasive bladder cancer treated with bacillus Calmette–Guérin is associated with higher risk of progression compared to primary T1 tumors. J. Urol.184(1), 81–86 (2010).
   Google Scholar
• Zlotta A, Fleshner N, Jewett M. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can. Urol. Assoc. J.3(6 Suppl. 4), S199–S205 (2009).
   PubMedGoogle Scholar
• Hall M, Chang S, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol.178(6), 2314–2330 (2007).
   PubMed Web of Science ®Google Scholar
• Joudi F, Smith B, O’Donnell M, Group NB-IPI. Final results from a national multicenter Phase II trial of combination bacillus Calmette–Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer. Urol. Oncol.24(4), 344–348 (2006).
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Russo P, Bochner B et al. Phase II trial of intravesical gemcitabine in bacille Calmette–Guérin-refractory transitional cell carcinoma of the bladder. J. Clin. Oncol.24(18), 2729–2734 (2006).
   PubMed Web of Science ®Google Scholar
• Denzinger S, Fritsche H, Otto W, Blana A, Wieland W, Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur. Urol.53(1), 146–152 (2008).
   PubMed Web of Science ®Google Scholar
• Huguet J, Crego M, Sabaté S, Salvador J, Palou J, Villavicencio H. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur. Urol.48(1), 53–59 (2005).
   PubMed Web of Science ®Google Scholar
• Wiesner C, Pfitzenmaier J, Faldum A, Gillitzer R, Melchior S, Thüroff J. Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy. BJU Int.95(3), 301–305 (2005).
   Google Scholar
• Amling C, Thrasher J, Frazier H, Dodge R, Robertson J, Paulson D. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J. Urol.151(1), 31–35 (1994).
   PubMed Web of Science ®Google Scholar
• Freeman J, Esrig D, Stein J et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer76(5), 833–839 (1995).
   PubMed Web of Science ®Google Scholar
• Stein J, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol.19(3), 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Shariat S, Karakiewicz P, Palapattu G et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J. Urol.176(6 Pt 1), 2414–2422 (2006).
   PubMed Web of Science ®Google Scholar
• Madersbacher S, Hochreiter W, Burkhard F et al. Radical cystectomy for bladder cancer today – a homogeneous series without neoadjuvant therapy. J. Clin. Oncol.21(4), 690–696 (2003).
   PubMed Web of Science ®Google Scholar
• Hautmann R, Gschwend J, de Petriconi R, Kron M, Volkmer B. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J. Urol.176(2), 486–492 (2006).
   PubMed Web of Science ®Google Scholar
• Leissner J, Ghoneim M, Abol-Enein H et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J. Urol.171(1), 139–144 (2004).
   PubMed Web of Science ®Google Scholar
• Hautmann R, Volkmer B, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J. Urol.27(3), 347–351 (2009).
   PubMed Web of Science ®Google Scholar
• Herr H, Sogani P. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J. Urol.166(4), 1296–1299 (2001).
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Vora K, Kaag M et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur. Urol.56(6), 903–910 (2009).
   PubMed Web of Science ®Google Scholar
• Weiss C, Wolze C, Engehausen D et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J. Clin. Oncol.24(15), 2318–2324 (2006).
   PubMed Web of Science ®Google Scholar
• Harland S, Kynaston H, Grigor K et al. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J. Urol.178(3 Pt 1), 807–813 (2007).
   Google Scholar
• Lamm D, Blumenstein B, Crissman J et al. Maintenance bacillus Calmette–Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol.163(4), 1124–1129 (2000).
   PubMed Web of Science ®Google Scholar
• Lawrentschuk N, Colombo R, Hakenberg O et al. Prevention and management of complications following radical cystectomy for bladder cancer. Eur. Urol.57(6), 983–1001 (2010).
   PubMed Web of Science ®Google Scholar
• Kulkarni G, Finelli A, Fleshner N, Jewett M, Lopushinsky S, Alibhai S. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med.4(9), e284 (2007).
   PubMedGoogle Scholar
• Sylvester R, van der Meijden A, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol.49(3), 466–477 (2006).
   PubMed Web of Science ®Google Scholar
• Andius P, Johansson S, Holmäng S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology70(4), 758–762 (2007).
   PubMed Web of Science ®Google Scholar
• Smits G, Schaafsma E, Kiemeney L, Caris C, Debruyne F, Witjes J. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology52(6), 1009–1013 (1998).
   PubMed Web of Science ®Google Scholar
• Divrik R, Sahin A, Altok M, Unlü N, Zorlu F. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer. J. Urol.178(3 Pt 1), 802–806 (2007).
   Google Scholar
• Herr H, Dalbagni G. Defining bacillus Calmette–Guérin refractory superficial bladder tumors. J. Urol.169(5), 1706–1708 (2003).
   PubMed Web of Science ®Google Scholar
• Karl A, Stepp H, Willmann E et al. Optical coherence tomography for bladder cancer – ready as a surrogate for optical biopsy? Results of a prospective mono-centre study. Eur. J. Med. Res.15(3), 131–134 (2010).
   PubMed Web of Science ®Google Scholar
• Sonn G, Jones S, Tarin T et al. Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. J. Urol.182(4), 1299–1305 (2009).
   PubMed Web of Science ®Google Scholar
• Ehdaie B, Theodorescu D. Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis. Expert Rev. Anticancer Ther.8(7), 1103–1110 (2008).
   PubMed Web of Science ®Google Scholar
• Hendricksen K, Witjes J. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer. Curr. Opin. Urol.17(5), 352–357 (2007).
   PubMed Web of Science ®Google Scholar
• Addeo R, Caraglia M, Bellini S et al. Randomized Phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J. Clin. Oncol.28(4), 543–548 (2010).
   PubMed Web of Science ®Google Scholar
• Jain A, Phillips R, Scally A, Lenaz G, Beer M, Puri R. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Urology73(5), 1083–1086 (2009).
   PubMed Web of Science ®Google Scholar
• Witjes A, Hendricksen K, Gofrit O, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J. Urol.27(3), 319–324 (2009).
   PubMed Web of Science ®Google Scholar
• Liguori G, Trombetta C, Pomara G et al. Major invasive surgery for urologic cancer in octogenarians with comorbid medical conditions. Eur. Urol.51(6), 1600–1604 (2007).
   PubMedGoogle Scholar
• Boström P, Kössi J, Laato M, Nurmi M. Risk factors for mortality and morbidity related to radical cystectomy. BJU Int.103(2), 191–196 (2008).
   Google Scholar
• Barbieri C, Lee B, Cookson M et al. Association of procedure volume with radical cystectomy outcomes in a nationwide database. J. Urol.178(4 Pt 1), 1418–1421 (2007).
   PubMed Web of Science ®Google Scholar
• Konety B, Allareddy V, Herr H. Complications after radical cystectomy: analysis of population-based data. Urology68(1), 58–64 (2006).
   PubMed Web of Science ®Google Scholar
• Hautmann R, Abol-Enein H, Hafez K et al. Urinary diversion. Urology69(Suppl. 1), 17–49 (2007).
   PubMed Web of Science ®Google Scholar
• Kefer J, Cherullo E, Jones J, Gong M, Campbell S. Prostate-sparing cystectomy: has Pandora’s box been opened? Expert Rev. Anticancer Ther.7(7), 1003–1014 (2007).
   PubMed Web of Science ®Google Scholar
• Hekal I, El-Bahnasawy M, Mosbah A, El-Assmy A, Shaaban A. Recoverability of erectile function in post-radical cystectomy patients: subjective and objective evaluations. Eur. Urol.55(2), 275–283 (2009).
   Google Scholar
• Puppo P, Introini C, Bertolotto F, Naselli A. Potency preserving cystectomy with intrafascial prostatectomy for high risk superficial bladder cancer. J. Urol.179(5), 1727–1732 (2008).
   Google Scholar